HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study

BACKGROUND/AIMS: The ideal end point of treatment for chronic hepatitis B virus (HBV) infection is sustained off-therapy hepatitis B surface antigen (HBsAg) loss with or even without seroconversion to anti-HBs. We investigated the role of adding PEGylated interferon (PEG IFN) to ongoing tenofovir tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Ashgar, Hamad, Peedikayil, Musthafa C., Al Quaiz, Mohammed, Al Sohaibani, Fahad, Al Fadda, Abdulrahman, Khan, Mohammed Q., Thoralsson, Einar, Al Thawadi, Sahar, Al Jedai, Ahmed, Al Kahtani, Khalid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470379/
https://www.ncbi.nlm.nih.gov/pubmed/28611343
http://dx.doi.org/10.4103/sjg.SJG_541_16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5470379/
https://www.ncbi.nlm.nih.gov/pubmed/28611343
http://dx.doi.org/10.4103/sjg.SJG_541_16

Ejemplares similares